Literature DB >> 18670639

Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression.

Jennifer Kl Colby1, Russell D Klein, Mark J McArthur, Claudio J Conti, Kaoru Kiguchi, Toru Kawamoto, Penny K Riggs, Amy I Pavone, Janet Sawicki, Susan M Fischer.   

Abstract

Cyclooxygenase-2 (COX-2) overexpression is an established factor linking chronic inflammation with metaplastic and neoplastic change in various tissues. We generated transgenic mice (BK5.COX-2) in which elevation of COX-2 and its effectors trigger a metaplasia-dysplasia sequence in exocrine pancreas. Histologic evaluation revealed a chronic pancreatitis-like state characterized by acinar-to-ductal metaplasia and a well-vascularized fibroinflammatory stroma that develops by 3 months. By 6 to 8 months, strongly dysplastic features suggestive of pancreatic ductal adenocarcinoma emerge in the metaplastic ducts. Increased proliferation, cellular atypia, and loss of normal cell/tissue organization are typical features in transgenic pancreata. Alterations in biomarkers associated with human inflammatory and neoplastic pancreatic disease were detected using immunohistochemistry. The abnormal pancreatic phenotype can be completely prevented by maintaining mice on a diet containing celecoxib, a well-characterized COX-2 inhibitor. Despite the high degree of atypia, only limited evidence of invasion to adjacent tissues was observed, with no evidence of distant metastases. However, cell lines derived from spontaneous lesions are aggressively tumorigenic when injected into syngeneic or nude mice. The progressive nature of the metaplastic/dysplastic changes observed in this model make it a valuable tool for examining the transition from chronic inflammation to neoplasia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18670639      PMCID: PMC2481568          DOI: 10.1593/neo.08330

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  83 in total

1.  Acinar-to-ductal metaplasia in pancreatic cancer development.

Authors:  Roland M Schmid
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 2.  Matrix metalloproteinases: effectors of development and normal physiology.

Authors:  T H Vu; Z Werb
Journal:  Genes Dev       Date:  2000-09-01       Impact factor: 11.361

3.  Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice.

Authors:  C H Liu; S H Chang; K Narko; O C Trifan; M T Wu; E Smith; C Haudenschild; T F Lane; T Hla
Journal:  J Biol Chem       Date:  2001-03-07       Impact factor: 5.157

4.  Cyclooxygenase-2 expression in human pancreatic adenocarcinomas.

Authors:  M T Yip-Schneider; D S Barnard; S D Billings; L Cheng; D K Heilman; A Lin; S J Marshall; P L Crowell; M S Marshall; C J Sweeney
Journal:  Carcinogenesis       Date:  2000-02       Impact factor: 4.944

5.  Acute pancreatitis signals activation of apoptosis-associated and survival genes in mice.

Authors:  G Gomez; H M Lee; Q He; E W Englander; T Uchida; G H Greeley
Journal:  Exp Biol Med (Maywood)       Date:  2001-07

6.  Barrett's metaplasia.

Authors:  J A Jankowski; R F Harrison; I Perry; F Balkwill; C Tselepis
Journal:  Lancet       Date:  2000-12-16       Impact factor: 79.321

7.  Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases.

Authors:  Niels Smakman; Onno Kranenburg; Jan M Vogten; Alexander L A Bloemendaal; Paul van Diest; Inne H M Borel Rinkes
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

8.  COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin.

Authors:  Stefano Cascinu; Mario Scartozzi; Giovanna Carbonari; Chiara Pierantoni; Lorena Verdecchia; Cinzia Mariani; Michela Squadroni; Stefania Antognoli; Rosa Rita Silva; Riccardo Giampieri; Rossana Berardi
Journal:  Am J Clin Oncol       Date:  2007-10       Impact factor: 2.339

9.  Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice.

Authors:  Toru Nakamura; Toshio Kuwai; Jang-Seong Kim; Dominic Fan; Sun-Jin Kim; Isaiah J Fidler
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

10.  In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia.

Authors:  Oliver Strobel; Yuval Dor; Janivette Alsina; Amy Stirman; Gregory Lauwers; Amanda Trainor; Carlos Fernández-Del Castillo; Andrew L Warshaw; Sarah P Thayer
Journal:  Gastroenterology       Date:  2007-09-14       Impact factor: 22.682

View more
  44 in total

1.  Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer.

Authors:  Sanjeev Banerjee; Asfar S Azmi; Subhash Padhye; Marjit W Singh; Jubaraj B Baruah; Philip A Philip; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Pharm Res       Date:  2010-04-27       Impact factor: 4.200

Review 2.  Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.

Authors:  Lawrence M Knab; Paul J Grippo; David J Bentrem
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 3.  Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward.

Authors:  David G Menter; Richard L Schilsky; Raymond N DuBois
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

4.  Transgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands.

Authors:  Jie Tian; Isabel Lambertz; Thomas R Berton; Joyce E Rundhaug; Kaoru Kiguchi; Stephanie H Shirley; John Digiovanni; Claudio J Conti; Susan M Fischer; Robin Fuchs-Young
Journal:  Mol Carcinog       Date:  2011-10-17       Impact factor: 4.784

Review 5.  Deploying mouse models of pancreatic cancer for chemoprevention studies.

Authors:  Paul J Grippo; David A Tuveson
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-02

6.  Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer.

Authors:  Jingjing Gong; Jianping Xie; Roble Bedolla; Paul Rivas; Divya Chakravarthy; James W Freeman; Robert Reddick; Scott Kopetz; Amanda Peterson; Huamin Wang; Susan M Fischer; Addanki P Kumar
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

7.  Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor.

Authors:  Chantale Charo; Vijaykumar Holla; Thiruvengadam Arumugam; Rosa Hwang; Peiying Yang; Raymond N Dubois; David G Menter; Craig D Logsdon; Vijaya Ramachandran
Journal:  Pancreas       Date:  2013-04       Impact factor: 3.327

8.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

9.  Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.

Authors:  Weiying Zhang; Nivedita Nandakumar; Yuhao Shi; Mark Manzano; Alias Smith; Garrett Graham; Swati Gupta; Eveline E Vietsch; Sean Z Laughlin; Mandheer Wadhwa; Mahandranauth Chetram; Mrinmayi Joshi; Fen Wang; Bhaskar Kallakury; Jeffrey Toretsky; Anton Wellstein; Chunling Yi
Journal:  Sci Signal       Date:  2014-05-06       Impact factor: 8.192

10.  Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity.

Authors:  Nina Mayorek; Nili Naftali-Shani; Myriam Grunewald
Journal:  PLoS One       Date:  2010-09-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.